Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5905.074 | 0.9488 | 0.8820 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5905.074 | 0.9997 | 0.9994 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5905.074 | 0.9997 | 0.9994 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5905.074 | 0.5291 | -0.0421 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5905.074 | 0.5291 | -0.0421 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5905.074 | 0.4422 | -0.2216 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5905.074 | 0.4422 | -0.2216 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5905.074 | 0.3191 | -0.4662 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5905.074 | 0.3191 | -0.4662 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5905.074 | 0.2059 | -0.6784 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5905.074 | 0.2059 | -0.6784 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5905.074 | 0.0953 | -0.8680 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5905.074 | 0.0953 | -0.8680 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5905.074 | 0.1133 | -0.8389 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 5905.074 | 0.1133 | -0.8389 | 0.8648 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5906.074 | 1.0108 | 1.0337 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5906.074 | 1.0108 | 1.0337 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5906.074 | 1.0040 | 1.0124 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5906.074 | 1.0040 | 1.0124 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5906.074 | 1.0679 | 1.2146 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5906.074 | 1.0679 | 1.2146 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5906.074 | 0.7649 | 0.3193 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5906.074 | 0.7649 | 0.3193 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5906.074 | 0.4292 | -0.4619 | 0.6442 | |
| BT-474 | HER2amp | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5906.074 | 0.4292 | -0.4619 | 0.6442 |